Schlidt is the cofounder and managing partner at Palo Santo, a venture capital fund focused exclusively on the advancement of psychedelic therapies for the treatment of mental health disorders and beyond. Based on his own experience with severe depression as a teenager, Schlidt's goal is to steward the most efficacious psychedelic therapies towards FDA approval so that patients may safely, legally, and affordably access these medicines. He has deployed $25 million into 20 companies including Gilgamesh, Journey Clinical and Sensorium.

Show Highlights:

-The potential of psychedelics for mental health treatment.

-Tim's story leading to investment in psychedelics.-Why to practice safe and supervised use of psychedelics in treatment.-Legal and ethical considerations around the use of psychedelics.

-What are challenges in developing psychedelics?-Predicitons for psychedelics in mainstream medicine.

-Psychedelics for therapeutic and personal growth.